Inactive Instrument

Intercept Pharmaceuticals, Inc.

Equities

ICPT

US45845P1084

Biotechnology & Medical Research

INTERCEPT PHARMACEUTICALS, INC. : Change in Directors or Principal Officers (form 8-K)

January 21, 2021 at 03:02 am IST

Item 5.02. Departure of Directors or Certain Officers; Election of Directors;


            Appointment of Certain Officers; Compensatory Arrangements of Certain
            Officers.

(b) On January 16, 2021, Richard Kim notified Intercept Pharmaceuticals, Inc. (the "Company") of his decision to resign from his position as the Company's President, U.S. Commercial & Strategic Marketing, effective February 15, 2021, in order to pursue other opportunities. Mr. Kim's resignation was not the result of any disagreement regarding any matter related to the Company's operations, policies or practices.

Latest news about Intercept Pharmaceuticals, Inc.

Intercept Presents New Sub-Analyses of Phase 3 Poise Data Showcasing the Effect of Oca on Key Liver Biomarkers in Patients with PBC at EASL Congress 2024	04/06	CI
Intercept Pharmaceuticals, Inc. Presents New Sub-Analyses of Phase 3 POISE Data Showcasing the Effect of OCA on Key Liver Biomarkers and Fibrosis in Patients with PBC at Digestive Disease Week 2024	20/05	CI
Intercept Pharmaceuticals, Inc. Presents New Data Demonstrating the Impact of OCA-Bezafibrate Combination Therapy on Alp and Metabolic Outcomes After Six Months of Treatment At Digestive Disease Week®? 2024	18/05	CI
North American Morning Briefing : Caution Dominates Ahead of CPI Print	14/11	DJ
Intercept Announces New Phase 2 Data Showing Significant Impact of OCA-Bezafibrate Combination on Normalization of Multiple Key Biomarkers of PBC-Induced Liver Damage At AASLD the Liver Meeting® 2023	13/11	CI
Intercept Pharmaceuticals, Inc. Announces New Findings from Long-Term Extension of Landmark POISE Trial in PBC Showing Importance of Biomarkers Beyond ALP at AASLD the Liver Meeting® 2023	10/11	CI
Intercept Pharmaceuticals, Inc.(NasdaqGS:ICPT) dropped from NASDAQ Composite Index	08/11	CI
Intercept Pharmaceuticals, Inc.(NasdaqGS:ICPT) dropped from S&P TMI Index	08/11	CI
Intercept Pharmaceuticals, Inc.(NasdaqGS:ICPT) dropped from S&P Global BMI Index	08/11	CI
Intercept Pharmaceuticals, Inc.(NasdaqGS:ICPT) dropped from S&P Biotechnology Select Industry Index	08/11	CI
Alfasigma S.p.A. completed the acquisition of Intercept Pharmaceuticals, Inc..	08/11	CI
North American Morning Briefing : Higher Bond -2-	07/11	DJ
Intercept Pharmaceuticals, Inc.(NasdaqGS:ICPT) dropped from NASDAQ Biotechnology Index	07/11	CI
Intercept Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	07/11	CI
Persephone Biosciences Appoints Daniel Bradbury as Chair of the Board of Directors	23/23/23	CI
North American Morning Briefing : Rising Oil -2-	28/23/28	DJ
UBS Raises Intercept Pharmaceuticals Price Target to $19 From $12, Maintains Neutral Rating	27/23/27	MT
HC Wainwright Downgrades Intercept Pharmaceuticals to Neutral From Buy, Price Target is $19	27/23/27	MT
Canaccord Genuity Downgrades Intercept Pharmaceuticals to Hold From Buy, Trims Price Target to $19 From $20	27/23/27	MT
RBC Raises Price Target on Intercept Pharmaceuticals to $19 From $12 on Deal to Be Bought by Alfasigma; Sector Perform Kept	27/23/27	MT
B. Riley Downgrades Intercept Pharmaceuticals to Neutral From Buy After Announced Sale to Alfasigma, Lifts PT to $19 From $15	27/23/27	MT
Sector Update: Health Care Stocks Lower Late Tuesday Afternoon	27/23/27	MT
Sector Update: Health Care Stocks Declining in Afternoon Trading	26/23/26	MT
Intercept Pharmaceuticals Agrees to be Acquired by Alfasigma for $19 Per Share; Stock Soars Pre-Bell	26/23/26	MT
Italy's Alfasigma to buy drugmaker Intercept for nearly $800 mln	26/23/26	RE

Chart Intercept Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

Intercept Pharmaceuticals, Inc. is a biopharmaceutical company that is focused on the development and commercialization of therapeutics to treat progressive non-viral liver diseases with unmet medical need utilizing its bile acid chemistry. Its product candidates include Ocaliva (obeticholic (OCA)) for liver fibrosis due to nonalcoholic steatohepatitis (NASH), OCA and Bezafibrate, and Other Product Candidates. The Company's marketed product, Ocaliva, is a farnesoid X receptor (FXR) agonist for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA or as monotherapy in adults unable to tolerate UDCA. The Company is evaluating tolerability of OCA in combination with bezafibrate in patients with PBC in a Phase II study outside of the United States. Its other compounds are in early stages of research and development pipeline including INT-787 compound, an FXR agonist is in a Phase IIa clinical trial.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	+15.20%	121B
REGENERON PHARMACEUTICALS, INC.	+19.67%	113B
ARGENX SE	+18.95%	26.02B
BIONTECH SE	-23.86%	19.39B
GENMAB A/S	-19.03%	15.91B
BEIGENE, LTD.	-20.90%	15.09B
WUXI APPTEC CO., LTD.	-46.14%	15.06B
SAREPTA THERAPEUTICS, INC.	+63.85%	14.93B
NEUROCRINE BIOSCIENCES, INC.	+4.49%	13.85B

Bio Therapeutic Drugs